Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 16/20 | 0.83 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.75 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | GALR3 | O60755 | 1/20 | 0.71 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.71 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.67 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.65 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.65 |
| ▸ | CDK1 | P06493 | 1/20 | 0.65 |
| ▸ | ROS1 | P08922 | 1/20 | 0.65 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.65 |
| ▸ | CDK2 | P24941 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodotubercidin SCHEMBL12618424 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL2786488 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL12505209 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL29383008 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL319225 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL13021361 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL12652819 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL8328935 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL29375718 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 | |
| Iodotubercidin SCHEMBL16978206 | 1.00 | ADK (0.83) | ADKSLC29A1DOT1LNPC1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834401-B2 | Treating and preventing diseases by modulating cell mechanics | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | disclosed |
| US-20220411458-A1 | TRANSLOCATION CONTROL ELEMENTS, REPORTER CODES, AND FURTHER MEANS FOR TRANSLOCATION CONTROL FOR USE IN NANOPORE SEQUENCING | Roche Sequencing Solutions, Inc. | 2022-12-29 | — | — | US | disclosed |
| CN-115317614-B | Application of ADK inhibitor in preparation of medicine for treating spinal cord injury | 暨南大学 | 2022-12-27 | — | — | CN | disclosed |
| CN-115317614-A | Application of ADK inhibitor in preparation of medicine for treating spinal cord injury | 暨南大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-114096540-A | Translocation control elements, reporter codes, and other means for translocation control for nanopore sequencing | 斯特拉托斯基因公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-11-04 | — | — | US | disclosed |
| US-10294262-B2 | 7-deazapurine nucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2019-05-21 | — | — | US | disclosed |
| US-10188633-B2 | Identification of small molecules that facilitate therapeutic exon skipping | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-29 | — | — | US | disclosed |
| US-7678892-B2 | Dye-labeled ribonucleotide triphosphates | APPLIED BIOSYSTEMS, LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070293662-A1 | Dye-labeled ribonucleotide triphosphates | APPLERA CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293662-A1 | Dye-labeled ribonucleotide triphosphates | APPLERA CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| US-7262029-B2 | Dye-labeled ribonucleotide triphosphates | APPLERA CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262029-B2 | Dye-labeled ribonucleotide triphosphates | APPLERA CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1480515-B1 | INBRED EMBRYONIC STEM-CELL DERIVED MICE | ARTEMIS PHARMACEUTICALS GMBH (DE) | 2005-10-19 | — | — | EP | disclosed |
| EP-1480515-A2 | INBRED EMBRYONIC STEM-CELL DERIVED MICE | ARTEMIS Pharmaceuticals GmbH (DE) | 2004-12-01 | — | — | EP | disclosed |
| US-20030204862-A1 | Inbred embryonic stem-cell derived mice | KUEHN RALF (DE) | 2003-10-30 | — | — | US | disclosed |
| WO-2003073843-A2 | INBRED EMBRYONIC STEM-CELL DERIVED MICE | ARTEMIS PHARMACEUTICALS GMBH (DE) | 2003-09-12 | — | — | WO | disclosed |
| WO-1994006438-A1 | ADENOSINE ANALOGUES AND METHOD OF INCREASING ADENOSINE RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10188633-B2 | Identification of small molecules that facilitate therapeutic exon skipping | RBM17, SMN1; SMN2, SNRPA1 | ADK 1993/4885SLC29A1 1465/4885DOT1L 4208/4885 |
| US-10294262-B2 | 7-deazapurine nucleosides for therapeutic uses | TPMT, TYMP, ENTPD5 | ADK 221/4885SLC29A1 6/4885DOT1L 689/4885 |
| US-20220411458-A1 | TRANSLOCATION CONTROL ELEMENTS, REPORTER CODES, AND FURTHER MEANS FOR TRANSLOCATION CONTROL FOR USE IN NANOPORE SEQUENCING | PHAX, DNTT, NSUN3 | ADK 1704/4885SLC29A1 11/4885DOT1L 4195/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | ADK 3917/4885SLC29A1 3859/4885DOT1L 864/4885 |
| US-11834401-B2 | Treating and preventing diseases by modulating cell mechanics | PKD1, MMP11, MMP13 | ADK 3649/4885SLC29A1 1598/4885DOT1L 3887/4885 |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | PER2, CRY1, ADORA2A | ADK 4/4885SLC29A1 450/4885DOT1L 1755/4885 |
| US-20070293662-A1 | Dye-labeled ribonucleotide triphosphates | DUT, POLRMT, SAMHD1 | ADK 327/4885SLC29A1 101/4885DOT1L 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.